Objectives-Some reports have described a decreased percentage of circulating
There is evidence of a decrease in CD8+ cells with age, both in absolute number and as a percentage of lymphocytes,'3 14 so controls should be matched for age, which is not addressed in some of the previous studies. ' 2 In some of the previous studies the patients with PMR/GCA were already receiving prednisolone at the time of T cell subset analysis.67
We have seen changes in T cell subtypes occurring with prednisolone in normal volunteers. 14a Blood samples taken seven hours after a single 20 To clarify the conflicting data from previous work, this study was designed to eliminate these variables.
Patients and methods
Thirty six patients with PMR/GCA were assessed before, during, and after treatment with prednisolone. Ages ranged from 51 to 87 years (median 70 years). Diagnosis was made according to the clinical criteria of Jones and Hazleman.'5 Increased erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) were not used as inclusion criteria, as these and other laboratory variables were to be studied, but in fact 34 of 36 patients did have an ESR above 30 mm/h or a CRP above 6 mg/l, or both. Serum creatine kinase and protein electrophoresis were normal in all patients with PMR.
These patients had blood samples taken between 1000 and 1400 hours, before treatment, and subsequently after 10 days, three weeks, six weeks, and three months of treatment, and thereafter every three months until treatment could be discontinued. Venesection was always carried out at the same time of day and before the daily.prednisolone dose. Treatment for PMR was begun with prednisolone 10-20 mg daily, or for GCA with prednisolone 40 mg daily. Prednisolone was prescribed as the enteric coated preparation and as a once daily dose in the morning. Subsequently the dose was reduced according to clinical disease activity.
Controls were matched for age and sex and consisted of healthy volunteers and patients with osteoarthritis. Ethical committee approval was obtained to approach the controls for blood tests. Control samples were collected between 1000 and 1400 hours.
All patients and controls were seen at Addenbrooke's Hospital and all blood samples were processed within six hours ofvenesection. The total white blood cell count and lymphocyte count were measured using routine techniques in the haematology department at Addenbrooke's Hospital. T cell subtypes were analysed by flow cytometry using a whole blood lysis technique. Total T cells were measured using antibodies to CD3 (Leu 4). Activated T cells were those CD3+ cells which coexpressed antibodies to HLA-DR. CD4+ cells were defined using Leu 3 and CD8+ cells using Leu 2. Natural killer cells were CD3-expressing CD 16/56 (Leu 1 I c+ 19) . All Duration of treatment (months) CD8+ T cells in controls and patients with polymyalgia rheumatic and giant cell arteritis (PMRIGCA) before and during treatment with prednisolone, after 10 days, six weeks, three months, and every three months thereafter (three week data points omittedfor clarity; for three week data see table 1). During treatment venesection was carried out before the daily dose ofprednisolone. Results expressed as percentage oflymphocytes (A) and as absolute numbers (B), medians plus interquartile range. * p<0O05 and NS=not significant compared with controls.
Pountain, Keogan, Brown, Hazleman often difficult, as any delay in the treatment of PMR/GCA may lead to irreversible complications such as blindness.'6 Hence recruiting untreated patients is not easy. We found that several patients seen rapidly for their first assessment and assumed to have received no corticosteroids had actually received the initial dose of prednisolone from their family doctor, and therefore were excluded from our study. This clinical history must be diligently sought and the magnitude of the effect of a single dose of corticosteroids appreciated.
Our work in normal volunteers'4a has shown that the effects of prednisolone on lymphocyte subsets occur in two phases. The initial effects (maximum at about seven hours after a 20 mg dose of enteric coated prednisolone) include a pronounced decrease in the absolute numbers of lymphocytes, total T cells, CD4+, and CD8+ cells. The effects of longer term prednisolone treatment are almost the opposite of the early effects-that is, at 72 hours the absolute numbers of total T cells, CD4+, and CD8+ cells are markedly increased, with a decrease in the percentage of CD8+ cells. These later effects begin to develop by 24 hours after the first dose of prednisolone. Before this study only acute lymphopenia (particularly of CD4+ cells) had been shown after a single dose of prednisolone in volunteers.'7 18 The same effect has been assumed by some to occur in longer term treatment with corticosteroids, whereas our study in normal volunteers shows that the later changes contrast markedly with the acute effects. Those studies in PMR/GCA where patients were already receiving prednisolone at the time of the initial analysis of T cell subtypes6 7 cannot give us useful information about CD8+ numbers in PMR/GCA per se. In those studies reporting a reduced percentage of CD8+ cells in PMR/GCA before treatment,3-5 the inadvertent inclusion of patients after even a single dose of prednisolone might render these results similarly misleading. Multicentre studies may be particularly prone to this factor, in that it is more difficult at a distance to ensure that no treatment has been given before the initial blood sample.
During follow up of treated PMR/GCA, T cell subtypes will again be critically altered by the interval since the previous dose of prednisolone. In this study T cells during treatment were measured before the daily dose of prednisolone, and this is reflected in the long term increase of CD8+ numbers seen in the figure, though this did not reach statistical significance. Other studies have not referred to the timing of the blood samples. If blood had been taken a few hours after a prednisolone dose, then the absolute numbers of CD8+ cells would be lowered, and if blood had been taken about 24 hours after a dose of prednisolone then CD8+ cells as a percentage of lymphocytes would be lowered. 14a Hence studies reporting prolonged lowering of CD8+ cells in PMR/GCA may be showing the effects of prednisolone rather than the effects of PMR/ GCA per se." Some differences in the results of studies in patients with PMR/GCA might be due to patient selection. In our study, an increased ESR and CRP were not required (as these tests were also being investigated). This might have resulted in our patients being less florid than other series, though, in fact, 34 of 36 patients did have either an increased ESR or CRP. We have addressed this problem by separately analysing the data from the most severe cases of PMR together with the cases of GCA proved by biopsy. Although absolute numbers of CD8+ cells were lowered in this group, this was part of a slight overall lymphopenia and there was no selective depletion of CD8+ cells. This suggests that studies incorporating only the most severe cases of PMR/GCA may be more likely to show a lowered lymphocyte count and therefore a lowered absolute CD8+ count. CD8+ cells as a percentage of lymphocytes, however, do not seem to be influenced by disease severity. It is therefore unlikely that patient selection accounts for the difference between this study and other studies showing a reduced percentage of CD8+ cells.
The differing results from studies of CD8+ cells in patients with PMR/GCA raises doubts about whether CD8+ cells are actually reduced in these patients. We have illustrated design flaws which could distort data and lead to an erroneous conclusion that CD8+ cells are reduced in PMR/GCA. Published results may also be distorted in favour of an abnormality of CD8+ cells, in that negative studies showing no such abnormality are less likely to be published.'9"21 We therefore conclude that the case that CD8+ cells are lowered in patients with PMR/GCA is not proved.
